Aclaris Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2016 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Aclaris Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2016 to Q2 2024.
Aclaris Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 27.4 %, a 0.65% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	27.4	-0.18	-0.65%	Jun 30, 2024
Q1 2024	29.9	+5.86	+24.3%	Mar 31, 2024
Q4 2023	31.5	+8.3	+35.8%	Dec 31, 2023
Q3 2023	32.1	+9.23	+40.4%	Sep 30, 2023
Q2 2023	27.6	+4.78	+21%	Jun 30, 2023
Q1 2023	24.1	-0.24	-0.99%	Mar 31, 2023
Q4 2022	23.2	-3.66	-13.6%	Dec 31, 2022
Q3 2022	22.8	-7.72	-25.3%	Sep 30, 2022
Q2 2022	22.8	-16.7	-42.2%	Jun 30, 2022
Q1 2022	24.3	-37.8	-60.8%	Mar 31, 2022
Q4 2021	26.9	-47.7	-64%	Dec 31, 2021
Q3 2021	30.6	-30.8	-50.2%	Sep 30, 2021
Q2 2021	39.5	-28.2	-41.7%	Jun 30, 2021
Q1 2021	62.1	-1.3	-2.05%	Mar 31, 2021
Q4 2020	74.5	+20.9	+39%	Dec 31, 2020
Q3 2020	61.3	+15.1	+32.7%	Sep 30, 2020
Q2 2020	67.7	+32.3	+91%	Jun 30, 2020
Q1 2020	63.4	+37.1	+141%	Mar 31, 2020
Q4 2019	53.6	+34.9	+186%	Dec 31, 2019
Q3 2019	46.2	+33.4	+260%	Sep 30, 2019
Q2 2019	35.4	+25.6	+260%	Jun 30, 2019
Q1 2019	26.3	+18.6	+243%	Mar 31, 2019
Q4 2018	18.8	+12.5	+199%	Dec 31, 2018
Q3 2018	12.9	+7.68	+149%	Sep 30, 2018
Q2 2018	9.85	+5.34	+118%	Jun 30, 2018
Q1 2018	7.66	+3.01	+64.7%	Mar 31, 2018
Q4 2017	6.26	+1.2	+23.7%	Dec 31, 2017
Q3 2017	5.16	+0.43	+9.09%	Sep 30, 2017
Q2 2017	4.51	-1.35	-23%	Jun 30, 2017
Q1 2017	4.65			Mar 31, 2017
Q4 2016	5.06			Dec 31, 2016
Q3 2016	4.73			Sep 30, 2016
Q2 2016	5.87			Jun 30, 2016

* An asterisk sign (*) next to the value indicates that the value is likely invalid.